C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test
The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
- The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
- "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense.
- "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled."
- As always, we remain committed to providing our customers with the best possible solution for at-home testing," added Cox.